Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.26T
Market cap1.26T
Price-Earnings ratio
40.36
Price-Earnings ratio40.36
Dividend yield
0.58%
Dividend yield0.58%
Average volume
3.30M
Average volume3.30M
High today
$1,226.50
High today$1,226.50
Low today
$1,191.08
Low today$1,191.08
Open price
$1,201.73
Open price$1,201.73
Volume
932.93K
Volume932.93K
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$629.40
52 Week low$629.40

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,220.64, giving the company a market capitalization of 1.26T. It carries a P/E multiple of 40.36 and pays a dividend yield of 0.58%.

On 2026-08-12, Eli Lilly(LLY) stock traded between a low of $1,191.08 and a high of $1,226.50. Shares are currently priced at $1,220.64, which is +2.5% above the low and -0.5% below the high.

The Eli Lilly(LLY)'s current trading volume is 932.93K, compared to an average daily volume of 3.3M.

During the past year, Eli Lilly(LLY) stock moved between $629.40 at its lowest and $1,249.45 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $629.40 at its lowest and $1,249.45 at its peak.

LLY News

Simply Wall St 2h
Veeva Systems Expands AI CRM Role With Eli Lilly Win Is Its Moat Deepening?

Eli Lilly and Company has committed to roll out Veeva Vault CRM across its global operations, adopting Veeva’s agentic, AI-enabled commercial platform as its co...

Veeva Systems Expands AI CRM Role With Eli Lilly Win Is Its Moat Deepening?
Investor's Business Daily 4h
IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Arista Beats Views 8/08/2026 Among the best stocks in earnings performance, highly rated...

IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point
TipRanks 4h
Eli Lilly Sues Six Companies Over Weight-Loss Drug Sales

Pharmaceutical giant Eli Lilly (LLY) has filed lawsuits against six U.S. companies that it accuses ​of illegally selling black-market versions of its experiment...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More LLY News

MarketWatch 5h
Eli Lilly is suing pharmacies and peptide vendors over premature sales of the next big weight-loss drug: retatrutide

Eli Lilly has sued six companies, saying they are illegally selling versions of the unapproved weight-loss drug retatrutide. Eli Lilly is suing six pharmacies...

Eli Lilly is suing pharmacies and peptide vendors over premature sales of the next big weight-loss drug: retatrutide
TipRanks 6h
Eli Lilly Sues Six U.S. Firms Over Black Market Sales of Unapproved Obesity Drug

Eli Lilly & Co. (LLY), the manufacturer of weight-loss drugs Mounjaro and Zepbound, has filed six lawsuits against U.S. businesses for illegally selling version...

Bloomberg 9h
Lilly Escalates Its Fight Against Black Market Weight-Loss Shots

Eli Lilly & Co. is stepping up its fight against a booming black market for retatrutide, an experimental drug that the company is counting on to expand its cruc...

Lilly Escalates Its Fight Against Black Market Weight-Loss Shots
Simply Wall St 15h
Eli Lilly Opens $50 A Month Medicare Access To Obesity Drugs

Amazon Pharmacy launches a program to offer Eli Lilly (NYSE: LLY) weight-loss drug Zepbound to eligible Medicare patients for US$50 per month using a new federa...

Eli Lilly Opens $50 A Month Medicare Access To Obesity Drugs
Nasdaq 18h
Better Buy: Eli Lilly vs. Novo Nordisk

Key Points Eli Lilly has a stronger GLP-1 portfolio and pipeline than Novo Nordisk. Eli Lilly also has a better lineup outside the diabetes and weight-loss ar...

Better Buy: Eli Lilly vs. Novo Nordisk
TipRanks 1d
Eli Lilly’s Weight-Loss Pill Is Approved for Sale in the United Kingdom

Eli Lilly’s (LLY) stock was up about 2% in early trading on Aug. 11 on news that the company’s weight loss pill Foundayo has been approved for sale in the Unite...

Simply Wall St 2d
What Does Eli Lilly Gain From Its Oncology Push And New Funding Bet?

Eli Lilly (NYSE: LLY) has entered a new clinical trial collaboration with Amplia Therapeutics to test a novel drug combination in non-small cell lung cancer. T...

What Does Eli Lilly Gain From Its Oncology Push And New Funding Bet?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.